Last reviewed 2026-04-23 · How we verify

Triptorelin (I.N.N.)

Triptorelin is a GnRH agonist that stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, initially increasing sex hormone levels before causing sustained suppression through receptor desensitization.

Triptorelin is a GnRH agonist that stimulates the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, initially increasing sex hormone levels before causing sustained suppression through receptor desensitization. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids.

At a glance

Mechanism of action

Triptorelin binds to GnRH receptors in the anterior pituitary, initially triggering release of LH and FSH. With continuous exposure, the pituitary becomes desensitized and downregulates GnRH receptors, resulting in suppression of gonadal sex hormone production (testosterone in males, estrogen in females). This sustained suppression is therapeutically useful in hormone-dependent conditions.

Approved indications

• Advanced prostate cancer
• Endometriosis
• Uterine fibroids
• Central precocious puberty

Common side effects

• Hot flashes
• Injection site reaction
• Headache
• Fatigue
• Decreased libido
• Erectile dysfunction
• Gynecomastia

Key clinical trials

• Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Triptorelin (I.N.N.) CI brief — competitive landscape report
• Triptorelin (I.N.N.) updates RSS · CI watch RSS
• Ipsen portfolio CI